1. Home
  2. ISPC vs SCNI Comparison

ISPC vs SCNI Comparison

Compare ISPC & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iSpecimen Inc.

ISPC

iSpecimen Inc.

HOLD

Current Price

$0.37

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

SCNI

Scinai Immunotherapeutics Ltd.

HOLD

Current Price

$0.73

Market Cap

4.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISPC
SCNI
Founded
2009
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
4.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ISPC
SCNI
Price
$0.37
$0.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
541.1K
59.7K
Earning Date
11-17-2025
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
$3,352,744.00
$1,147,000.00
Revenue This Year
$35.93
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.67
Revenue Growth
N/A
303.87
52 Week Low
$0.36
$0.70
52 Week High
$3.38
$6.18

Technical Indicators

Market Signals
Indicator
ISPC
SCNI
Relative Strength Index (RSI) 31.06 31.57
Support Level $0.36 $0.70
Resistance Level $0.44 $0.85
Average True Range (ATR) 0.04 0.10
MACD 0.00 -0.03
Stochastic Oscillator 6.47 3.33

Price Performance

Historical Comparison
ISPC
SCNI

About ISPC iSpecimen Inc.

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Share on Social Networks: